JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan maintains a Market Outperform rating on Benitec Biopharma (NASDAQ:BNTC) and raises the price target from $4 to $6.
September 26, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benitec Biopharma's price target has been raised from $4 to $6 by JMP Securities, maintaining a Market Outperform rating.
The raised price target and maintained Market Outperform rating by JMP Securities indicates a positive outlook for Benitec Biopharma. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100